A new analysis of TREAT shows that baseline characteristics and postrandomization factors do not explain the increased incidence of stroke in patients assigned to darbepoetin alfa. Baseline characteristics that predicted the risk of stroke in the overall TREAT population did not modify the risk of stroke associated with darbepoetin alfa in interaction analyses. Similarly, postrandomization factors, including blood pressure, hemoglobin levels, platelet count and treatment dose, did not explain the increased risk of darbepoetin alfa-related stroke.
ORIGINAL RESEARCH PAPER
Skali, H. et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Experience. Circulation doi:10.1161/CIRCULATIONAHA.111.030411
Rights and permissions
About this article
Cite this article
Cause of increased risk of stroke related to darbepoetin alfa still uncertain. Nat Rev Nephrol 8, 62 (2012). https://doi.org/10.1038/nrneph.2011.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.202